Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma

Completed

• Conditions: Renal Cell Carcinoma; Hepatocellular Carcinoma

• Registration Number: NCT01482520
• Lead Sponsor: Samsung Medical Center

Brief Summary

All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study.

No additional treatment or intervention will be conducted except for blood sampling that will be limited to one time only.

Blood samples (10 cc in volume) will be collected from all study participants once they provided written informed consent form. DNA will be extracted from peripheral blood samples using DNA isolation kit.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-08
• Study First Submitted: 2011-11-14
• Study First Submitted QC: 2011-11-29
• Study First Posted: 2011-11-30
• Primary Completion: 2013-09
• Study Completion: 2013-10
• Status Verified: 2014-05
• Last Update Submitted: 2014-05-12
• Last Update Posted: 2014-05-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Genotypes	36months	To define genotypes of HCC and RCC patients who will likely to response to molecular targeted therapy.; To define genotypes associated with adverse events from molecular targeted.; To identify genotypes which will predict survival or disease-free survival following molecular targeted therapy.

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of